Table 2

Measures of clinical outcomes after the therapeutic intervention

Control groupOutcomeStudies, nWMD95% CIp Value
High-dose nesiritide
 PlaceboSVR (dynes/s/cm−5)2−305.17−493.96 to −116.380.002
SBP (mm Hg)2−6.87−11.01 to −2.730.001
 DobutamineDBP (mm Hg)1−6.3−12.39 to −0.210.04
SBP (mm Hg)1−6.3−12.39 to −0.210.04
Low-dose nesiritide
 PlaceboPCWP (mm Hg)3−4.35−4.35 to −3.33<0.00 001
SVR (dynes/s/cm−5)3−95.35−178.09 to −12.060.02
RAP (mm Hg)3−5.6−8.99 to −2.210.001
SCr (mg/dL)1−0.02−0.11 to 0.070.66
BUN (mg/dL)1−2.9−8.85 to 3.050.34
 DobutamineDBP (mm Hg)2−2.21−3.43 to −0.980.0004
 NitroglycerinPCWP (mm Hg)2−2.21−3.43 to −0.980.0004
RAP (mm Hg)1−2.2−3.45 to−0.950.0005
SBP (mm Hg)1−3.9−6.92 to −0.880.01
SCr (mg/dL)2−0.04−0.17 to 0.080.49
CrCl (mL/min)2−0.82−6.95 to 5.310.79
  • BUN, blood urea nitrogen; CrCl, creatinine clearance; DBP, diastolic blood pressure; PCWP, pulmonary capillary wedge pressure; RAP, right atrial pressure; SBP, systolic blood pressure; SCr, serum creatinine; SVR, systemic vascular resistance; WMD, weighted mean difference.